ARTES is a biopharmaceutical contract research & development organization engineering microbial cell lines and providing process development for bio-pharmaceutical products. On top, ARTES offers manufacturing of tox study material derived from bacteria or yeast.
With more than 20 years of business experience, a highly experienced team and a track record of products developed for and marketed by clients, ARTES is a well-established partner for many of the biggest names in the industry.
ARTES specializes in recombinant protein production, process and vaccine development from microbial expression systems. It is marketing the unique METAVAX® (dHepB-VLP) technology in combination with high-level yeast based antigen production. The technology platforms are known as well as safe, reliable and highly competitive. All platform technologies (cell lines and vaccines) ensure freedom-to-operate and are protected by patents and trade secrets.
ARTES operates worldwide from its 850m2 S1 facilities in Langenfeld. The facilities are fully equipped at highest standards for projects including cell line engineering based on yeast (Hansenula polymorpha, syn. Pichia angusta; Saccharomyces cerevisiae; Pichia pastoris) and bacterial (E. coli) expression platforms, up- and downstream process development ranging from 0.5 – 15 liter volume, supply of non-GMP bulk material (API) for activity and toxicity tests and technology transfer to cGMP facilities and scale-up support.
CategoriesView all Categories
Our Development Brochure
ARTES is a well-established R&D partner for the pharmaceutical industry. Our technology and know-how is secure...
ARTES continuously develops valuable biosimilar processes. All of them excel with safe, fast and ef cient prod...
Our Metavex Brochure
METAVAX® our proprietary platform to develop highly immunogenic chimeric VLP-based vaccines presenting custome...
Efficient Production of Secreted and Active Invertase
In our today’s society, sugar plays an eminent roll. In industrialized countries, it serves as energy provider...